Carasent (Q4 review): New products and sales initiatives to drive growth in 2026 - Redeye

Redeye retains its positive view of Carasent following the Q4 report. Trading at 21.8x and 14.4x EBITDA-CAPEX 2026-2027e, the premium relative to other listed Nordic SaaS companies has increased, as many have seen much greater share price declines than Carasent. However, 15% organic growth is high for profitable SaaS companies, and we believe Carasent is among the most AI-resilient.

Länk till analysen i sin helhet: https://www.redeye.se/research/1148481/carasent-q4-review-new-products-and-sales-initiatives-to-drive-growth-in-2026?utm_source=finwire&utm_medium=RSS